RemeGen Co (FRA:REG) Debt-to-Asset : 0.30 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:REG RemeGen Co Ltd FRA:REG
50 GF Score
Price €8.50
GF Value €25.42
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is RemeGen Co Debt-to-Asset?

RemeGen Co FRA:REG -2.34% 50 Debt-to-Asset is 0.30 as of Dec. 2025. GuruFocus rates FRA:REG with a GF Score™ of 50/100 and a GF Value™ of €25.42 (Possible Value Trap). The stock has 6 warning signs investors should review.

RemeGen Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €175.8 Mil. RemeGen Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €91.2 Mil. RemeGen Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2025 was €878.8 Mil. RemeGen Co's debt to asset for the quarter that ended in Dec. 2025 was 0.30.

RemeGen Co  (FRA:REG) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

RemeGen Co Debt-to-Asset Related Terms

RemeGen Co Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for RemeGen Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RemeGen Co Debt-to-Asset Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial 0.03 0.03 0.23 0.49 0.30

RemeGen Co Quarterly Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.49 0.46 0.30 0.30

FRA:REG vs VRTX, REGN, RVMD: Debt-to-Asset Comparison

For the Biotechnology subindustry, RemeGen Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Debt-to-Asset falls into.


FRA:REG
50GF Score
RemeGen Co Ltd FRA:REG
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RemeGen Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

RemeGen Co's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(175.792 + 91.169) / 878.841
=0.30

RemeGen Co's Debt-to-Asset for the quarter that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(175.792 + 91.169) / 878.841
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.30 mean?
RemeGen Co (FRA:REG) has a Debt-to-Asset of 0.30 as of Dec. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on RemeGen Co and its competitors.
Is RemeGen Co's Debt-to-Asset too high?
RemeGen Co's current Debt-to-Asset is 0.30. Overall, RemeGen Co has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Debt-to-Asset compare to VRTX and REGN?
RemeGen Co's Debt-to-Asset of 0.30 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on RemeGen Co and its competitors. RemeGen Co's current Debt-to-Asset is 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €25.42, compared to a current price of €8.50 — trading 66.5% below its estimated fair value. The current Debt-to-Asset is 0.30. RemeGen Co's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current Debt-to-Asset is 0.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RemeGen Co (FRA:REG) Overvalued in 2026?

Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued. The current stock price of €8.50 is trading 66.5% below its estimated GF Value™ of €25.42. GuruFocus considers RemeGen Co to be Possible Value Trap.

Key valuation signals for FRA:REG:

  • Debt-to-Asset: 0.30
  • GF Value™: €25.42 vs. price of €8.50 (66.5% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RemeGen Co Business Description

Address 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
50GF Score

Get the complete analysis for FRA:REG

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.50
Price
€25.42
GF Value